Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MabThera + Methotrexate in RA after DMARD failure
NCT02006706Phase 3Completed
- Sponsor
- Roche
- Start
- Aug 2006
- Primary completion
- Nov 2007
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in rheumatoid arthritis (RA), sponsored by Roche. Primary endpoint: Disease Activity Score Based on 28-Joint Count at 24 weeks. Started Aug 2006; status: completed.
02
Drugs
rituximab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02006706.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02006706.